

Search strategy

- Antiplatelet trialist's collaboration
- Cochrane systematic reviews on antithrombotic agents

n=27 trials^{3,5,7,12,14-37}

- Cochrane register of controlled clinical trials
- Pubmed

n=20 trials^{1,2,4,6,8-11,13,38-48}

Total 47 trials



Excluded trials

4 trials performed only in patients with atrial fibrillation or large artery occlusive disease¹⁻⁴

1 trial only abstract available.⁵

2 quasi randomized trials.^{6,7}

5 short term trials or surrogate outcomes.⁸⁻¹²

1 trial vascular outcomes not available.¹³

Total 13 trials



Included trials

N=34 with 36 aspirin arms

References

1. Chimowitz MI, Lynn MJ, Howlett-Smith H, Stern BJ, Hertzberg VS, Frankel MR, Levine SR, Chaturvedi S, Kasner SE, Benesch CG, Sila CA, Jovin TG, Romano JG. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. *N Engl J Med*. 2005;352:1305-16.
2. Marti-Fabregas J, Cocho D, Marti-Vilalta JL, Gich I, Belvis R, Bravo Y, Millan M, Castellanos M, Rodriguez-Campello A, Egido J, Geffner D, Gil-Nunez A, Marta J, Navarro R, Obach V, Palomeras E. Aspirin or anticoagulants in stenosis of the middle cerebral artery: A randomized trial. *Cerebrovasc Dis*. 2006;22:162-9.
3. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. *Lancet*. 1993;342:1255-62.
4. Sato H, Ishikawa K, Kitabatake A, Ogawa S, Maruyama Y, Yokota Y, Fukuyama T, Doi Y, Mochizuki S, Izumi T, Takekoshi N, Yoshida K, Hiramori K, Origasa H, Uchiyama S, Matsumoto M, Yamaguchi T, Hori M. Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan Atrial Fibrillation Stroke Trial. *Stroke*. 2006;37:447-51.
5. Stewart B, Shuaib A, Veloso F. Stroke prevention with warfarin or aspirin trial (SWAT). *Stroke*. 1998;29:304-304.
6. Lee TK, Lien IN, Ryu SJ, Lee KY, Hu HH, Tchen PH, Chen CJ, Wu SC, Chen YC. Secondary prevention of ischemic stroke with low dose acetylsalicylic acid. *J Formos Med Assoc*. 1990;89:635-44.
7. Matias-Guiu J, Alvarez-Sabin J, Codina A. [Comparative study of the effect of low-dosage acetylsalicylic acid and triflusal in the prevention of cardiovascular events among young adults with ischemic cerebrovascular disease]. *Rev Neurol*. 1997;25:1669-72.
8. Markus HS, Droste DW, Kaps M, Larrue V, Lees KR, Siebler M, Ringelstein EB. Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial. *Circulation*. 2005;111:2233-40.
9. Uchiyama S, Sone R, Nagayama T, Shibagaki Y, Kobayashi I, Maruyama S, Kusakabe K. Combination therapy with low-dose aspirin and ticlopidine in cerebral ischemia. *Stroke*. 1989;20:1643-7.
10. Maruyama S, Uchiyama S, Tohgi H, Hirai S, Ikeda Y, Shinohara Y, Matsuda T, Fujishima M, Kameyama M. A randomized trial of E5510 versus aspirin in patients with transient ischemic attacks. The Japanese E5510 TIA study-1 (JETS-1) Group. *Angiology*. 1995;46:999-1008.
11. Serebruany VL, Malinin AI, Ziai W, Pokov AN, Bhatt DL, Alberts MJ, Hanley DF. Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in patients after recent ischemic stroke: for the Plavix Use for Treatment of Stroke (PLUTO-Stroke) trial. *Stroke*. 2005;36:2289-92.
12. Taylor DW, Barnett HJ, Haynes RB, Ferguson GG, Sackett DL, Thorpe KE, Simard D, Silver FL, Hachinski V, Clagett GP, Barnes R, Spence JD. Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial. ASA and Carotid Endarterectomy (ACE) Trial Collaborators. *Lancet*. 1999;353:2179-84.
13. Pennese F, Palombo V, Taormina F, Fracalaglio L, Brillante C, Abate G. [Comparative study of ASA and heparan sulfate in the secondary prevention of cerebrovascular disorders]. *Minerva Med*. 1993;84:621-6.
14. Fields WS, Lemak NA, Frankowski RF, Hardy RJ. Controlled trial of aspirin in cerebral ischemia. *Stroke*. 1977;8:301-14.
15. Fields WS, Lemak NA, Frankowski RF, Hardy RJ. Controlled trial of aspirin in cerebral ischemia. Part II: surgical group. *Stroke*. 1978;9:309-19.

16. Reuther R, Dorndorf W, Loew D. Behandlung transitorisch-ischämischer Attacken mit Azetylsalizylsäure Ergebnisse einer Doppelblindstudie. *MMW Munch Med Wochenschr.* 1980;122:795-8.
17. A randomized trial of aspirin and sulfipyrazone in threatened stroke. The Canadian Cooperative Study Group. *N Engl J Med.* 1978;299:53-9.
18. Guiraud-Chaumeil B, Rascol A, David J, Boneu B, Clanet M, Bierme R. [Prevention of recurrences of cerebral ischemic vascular accidents by platelet antiaggregants. Results of a 3-year controlled therapeutic trial]. *Rev Neurol (Paris).* 1982;138:367-85.
19. Candelise L, Landi G, Perrone P, Bracchi M, Brambilla G. A randomized trial of aspirin and sulfipyrazone in patients with TIA. *Stroke.* 1982;13:175-9.
20. Bousser MG, Eschwege E, Haguenau M, Lefauconnier JM, Thibult N, Touboul D, Touboul PJ. "AICLA" controlled trial of aspirin and dipyridamole in the secondary prevention of atherothrombotic cerebral ischemia. *Stroke.* 1983;14:5-14.
21. Sorensen PS, Pedersen H, Marquardsen J, Petersson H, Heltberg A, Simonsen N, Munck O, Andersen LA. Acetylsalicylic acid in the prevention of stroke in patients with reversible cerebral ischemic attacks. A Danish cooperative study. *Stroke.* 1983;14:15-22.
22. Garde A, Samuelsson K, Fahlgren H, Hedberg E, Hjerne LG, Ostman J. Treatment after transient ischemic attacks: a comparison between anticoagulant drug and inhibition of platelet aggregation. *Stroke.* 1983;14:677-81.
23. Persantine Aspirin Trial in cerebral ischemia. Part II: Endpoint results. The American-Canadian Co-Operative Study group. *Stroke.* 1985;16:406-15.
24. High-dose acetylsalicylic acid after cerebral infarction. A Swedish Cooperative Study. *Stroke.* 1987;18:325-34.
25. Tohgi H, Murakami M. [Pathophysiology and treatment of thrombosis. (2) The effect of ticlopidine on TIA compared with aspirin. A double-blind, 12-month and open 24-month follow-up study]. *Nippon Naika Gakkai Zasshi.* 1987;76:49-52.
26. Boysen G, Sorensen PS, Juhler M, Andersen AR, Boas J, Olsen JS, Joensen P. Danish very-low-dose aspirin after carotid endarterectomy trial. *Stroke.* 1988;19:1211-5.
27. United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: interim results. UK-TIA Study Group. *Br Med J (Clin Res Ed).* 1988;296:316-20.
28. Smirne S. Triflusal in the prevention of cerebrovascular attacks. *Giornale di Gerontologia.* 1995;43:563-569.
29. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. The Dutch TIA Trial Study Group. *N Engl J Med.* 1991;325:1261-6.
30. Hass WK, Easton JD, Adams HP, Jr., Pryse-Phillips W, Molony BA, Anderson S, Kamm B. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. *N Engl J Med.* 1989;321:501-7.
31. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. *J Neurol Sci.* 1996;143:1-13.
32. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. *Lancet.* 1996;348:1329-39.
33. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group. *Ann Neurol.* 1997;42:857-65.
34. Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. The SALT Collaborative Group. *Lancet.* 1991;338:1345-9.
35. Matias-Guiu J, Ferro JM, Alvarez-Sabin J, Torres F, Jimenez MD, Lago A, Melo T. Comparison of triflusal and aspirin for prevention of vascular events in patients after cerebral infarction: the TACIP Study: a randomized, double-blind, multicenter trial. *Stroke.* 2003;34:840-8.

36. Culebras A, Rotta-Escalante R, Vila J, Dominguez R, Abiusi G, Famulari A, Rey R, Bauso-Tosselli L, Gori H, Ferrari J, Reich E. Triflusal vs aspirin for prevention of cerebral infarction: a randomized stroke study. *Neurology*. 2004;62:1073-80.
37. Mohr JP, Thompson JL, Lazar RM, Levin B, Sacco RL, Furie KL, Kistler JP, Albers GW, Pettigrew LC, Adams HP, Jr., Jackson CM, Pullicino P. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. *N Engl J Med*. 2001;345:1444-51.
38. Marti Masso JF, Lozano R. Nicardipine in the prevention of cerebral infarction. *Clin Ther*. 1990;12:344-51.
39. Li Y, Li D, Wang L. A prospective randomized controlled study on ticlopidine with aspirin for the prevention of ischemic cerebral stroke. *Journal of Clinical Neurology (Chinese)*. 2000;13:146-148.
40. Grottemeyer KH, Evers S, Fischer M, Husstedt IW. Piracetam versus acetylsalicylic acid in secondary stroke prophylaxis. A double-blind, randomized, parallel group, 2 year follow-up study. *J Neurol Sci*. 2000;181:65-72.
41. Li YZ, Li DN, Hu ZQ, Fan RY, Liu BM, Zhu SW, Cheng GZ, Wang SJ, Li CG, Zheng JL, Zhang SG, Ma RZ, Hu ZK, Cui BW, Chi HW. Multicenter controlled trial of aspirin in secondary prevention of ischemia cerebrovascular disease in aged. *Chinese Journal of Prevention and Control of Chronic Non-Communicable Disease*. 1997;5:221-224.
42. Lee TK, Chan KW, Huang ZS, Ng SK, Lin RT, Po HL, Yuan RY, Lai ML, Chang TW, Yan SH, Deng JC, Liu LH, Lee KY, Lie SK, Sung SM, Hu HH. Effectiveness of low-dose ASA in prevention of secondary ischemic stroke, the ASA Study Group in Taiwan. *Thromb Res*. 1997;87:215-24.
43. Steiner M, Glantz M, Lekos A. Vitamin E plus aspirin compared with aspirin alone in patients with transient ischemic attacks. *Am J Clin Nutr*. 1995;62:1381S-1384S.
44. Chairangsarit P, Sithinamsuwan P, Niyasom S, Udommongkol C, Nidhinandana S, Suwantamee J. Comparison between aspirin combined with dipyridamole versus aspirin alone within 48 hours after ischemic stroke event for prevention of recurrent stroke and improvement of neurological function: a preliminary study. *J Med Assoc Thai*. 2005;88 Suppl 3:S148-54.
45. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Flather MD, Haffner SM, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Brennan DM, Fabry-Ribaudo L, Booth J, Topol EJ. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. *N Engl J Med*. 2006;354:1706-17.
46. Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. *Lancet*. 2006;367:1665-73.
47. Gorelick PB, Richardson D, Kelly M, Ruland S, Hung E, Harris Y, Kittner S, Leurgans S. Aspirin and ticlopidine for prevention of recurrent stroke in black patients: a randomized trial. *Jama*. 2003;289:2947-57.
48. Shinohara Y, Nishimaru K, Sawada T, Terashi A, Handa S, Hirai S, Hayashi K, Tohgi H, Fukuuchi Y, Uchiyama S, Yamaguchi T, Kobayashi S, Kondo K, Otomo E, Gotoh F. Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS): A randomized, double-blind, aspirin-controlled trial. *Stroke*. 2008;39:1827-33.

Sup Table 2 List of selected original inclusion and exclusion criteria for included studies according to primary publication.

Name of study	Age limits	TIA inclusion permitted	Stroke inclusion permitted	Study excluded patients undergoing carotid surgery	Study excluded cardiac sources of emboli	Study excluded patients with coagulation disorders	Study excluded patients with contraindications for aspirin	Study excluded patients who required antithrombotic agents for other reasons
AITIA ^{1,2}	-	+	-	+	-	-	-	-
Reuther ³	-	+	+	+	+	+	+	-
Canadian coop ⁴	-	+	+	-	-	-	-	-
Toulouse TIA ⁵	-	+	-	-	+	-	+	+
Italian TIA ⁶	<70	+	-	-	+	-	+	+
AICLA ⁷	>50*	+	-	-	+	+	+	-
Danish Coop ⁸	<75	+	+	+	-	-	+	+
Garde ⁹	-	+	+	+	+	-	+	+
ACCSG ¹⁰	-	+	+	+	+	+	+	+
Swedish	-	-	+	-	+	-	-	+
Tohgi ¹²	-	+	-	-	-	-	-	-
Danish Low ¹³	-	+	+	-	-	-	+	+
Marti Masso ¹⁴	>40	+	+	-	+	-	-	+
UKTIA ^{15,16}	>40	+	+	-	+	+	+	+
SALT ¹⁷	50-79	-	+	+	+	-	+	+
TASS ¹⁸	>40	+	+	+	+	+	+	+
Dutch TIA ¹⁹	-	+	+	-	+	+	+	-
Smirne ²⁰	-	+	+	-	-	+	+	-

Steiner ²¹	>18	+	+	-	+	+	+	+
ESPS 2 ²²	>18	+	+	-	-	+	+	+
CAPRIE ²³	>20	-	+	+	+	+	+	+
SPIRIT ²⁴	-	+	+	+	+	+	+	+
Lee ²⁵	-	-	+	-	+	-	+	-
Li ²⁶	-	+	+	-	-	-	-	-
Grotemeyer ²⁷	45-70	+	+	-	+	-	-	-
Li ²⁸	-	+	+	-	-	-	-	-
WARSS ²⁹	30-85	-	+	+	+	+	+	-
AAASPS ³⁰	29-85	-	+	+	+	+	+	-
TACIP ³¹	>39	+	+	+	-	-	+	+
TAPIRSS ³²	>40	+	+	+	+	+	+	+
Chairangarit ³³	>45	-	+	-	+	+	+	-
ESPRIT ³⁴	-	+	+	+	+	+	+	-
CHARISMA ³⁵	>45	+	+	-	-	-	+	+
S-access ³⁷	>19	-	+	+	+	+	+	-

* age limit only for women

References

1. Fields WS, Lemak NA, Frankowski RF, Hardy RJ. Controlled trial of aspirin in cerebral ischemia. *Stroke*. 1977;8:301-14.
2. Fields WS, Lemak NA, Frankowski RF, Hardy RJ. Controlled trial of aspirin in cerebral ischemia. Part II: surgical group. *Stroke*. 1978;9:309-19.
3. Reuther R, Dorndorf W, Loew D. Behandlung transitorisch-ischämischer Attacken mit Azetylsalizylsäure Ergebnisse einer Doppelblindstudie. *MMW Munch Med Wochenschr*. 1980;122:795-8.
4. A randomized trial of aspirin and sulfinpyrazone in threatened stroke. The Canadian Cooperative Study Group. *N Engl J Med*. 1978;299:53-9.
5. Guiraud-Chaumeil B, Rascol A, David J, Boneu B, Clanet M, Bierme R. [Prevention of recurrences of cerebral ischemic vascular accidents by platelet antiaggregants. Results of a 3-year controlled therapeutic trial]. *Rev Neurol (Paris)*. 1982;138:367-85.

6. Candelise L, Landi G, Perrone P, Bracchi M, Brambilla G. A randomized trial of aspirin and sulfinpyrazone in patients with TIA. *Stroke*. 1982;13:175-9.
7. Bousser MG, Eschwege E, Haguenu M, Lefauconnier JM, Thibult N, Touboul D, Touboul PJ. "AICLA" controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia. *Stroke*. 1983;14:5-14.
8. Sorensen PS, Pedersen H, Marquardsen J, Petersson H, Heltberg A, Simonsen N, Munck O, Andersen LA. Acetylsalicylic acid in the prevention of stroke in patients with reversible cerebral ischemic attacks. A Danish cooperative study. *Stroke*. 1983;14:15-22.
9. Garde A, Samuelsson K, Fahlgren H, Hedberg E, Hjerne LG, Ostman J. Treatment after transient ischemic attacks: a comparison between anticoagulant drug and inhibition of platelet aggregation. *Stroke*. 1983;14:677-81.
10. Persantine Aspirin Trial in cerebral ischemia. Part II: Endpoint results. The American-Canadian Co-Operative Study group. *Stroke*. 1985;16:406-15.
11. High-dose acetylsalicylic acid after cerebral infarction. A Swedish Cooperative Study. *Stroke*. 1987;18:325-34.
12. Tohgi H, Murakami M. [Pathophysiology and treatment of thrombosis. (2) The effect of ticlopidine on TIA compared with aspirin. A double-blind, 12-month and open 24-month follow-up study]. *Nippon Naika Gakkai Zasshi*. 1987;76:49-52.
13. Boysen G, Sorensen PS, Juhler M, Andersen AR, Boas J, Olsen JS, Joensen P. Danish very-low-dose aspirin after carotid endarterectomy trial. *Stroke*. 1988;19:1211-5.
14. Marti Masso JF, Lozano R. Nifedipine in the prevention of cerebral infarction. *Clin Ther*. 1990;12:344-51.
15. United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: interim results. UK-TIA Study Group. *Br Med J (Clin Res Ed)*. 1988;296:316-20.
16. Farrell B, Godwin J, Richards S, Warlow C. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. *J Neurol Neurosurg Psychiatry*. 1991;54:1044-54.
17. Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. The SALT Collaborative Group. *Lancet*. 1991;338:1345-9.
18. Hass WK, Easton JD, Adams HP, Jr., Pryse-Phillips W, Molony BA, Anderson S, Kamm B. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. *N Engl J Med*. 1989;321:501-7.
19. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. The Dutch TIA Trial Study Group. *N Engl J Med*. 1991;325:1261-6.
20. Smirne S. Triflusal in the prevention of cerebrovascular attacks. *Giornale di Gerontologia*. 1995;43:563-569.
21. Steiner M, Glantz M, Lekos A. Vitamin E plus aspirin compared with aspirin alone in patients with transient ischemic attacks. *Am J Clin Nutr*. 1995;62:1381S-1384S.
22. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. *J Neurol Sci*. 1996;143:1-13.
23. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. *Lancet*. 1996;348:1329-39.
24. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group. *Ann Neurol*. 1997;42:857-65.

25. Lee TK, Chan KW, Huang ZS, Ng SK, Lin RT, Po HL, Yuan RY, Lai ML, Chang TW, Yan SH, Deng JC, Liu LH, Lee KY, Lie SK, Sung SM, Hu HH. Effectiveness of low-dose ASA in prevention of secondary ischemic stroke, the ASA Study Group in Taiwan. *Thromb Res.* 1997;87:215-24.
26. Li YZ, Li DN, Hu ZQ, Fan RY, Liu BM, Zhu SW, Cheng GZ, Wang SJ, Li CG, Zheng JL, Zhang SG, Ma RZ, Hu ZK, Cui BW, Chi HW. Multicenter controlled trial of aspirin in secondary prevention of ischemia cerebrovascular disease in aged. *Chinese Journal of Prevention and Control of Chronic Non-Communicable Disease.* 1997;5:221-224.
27. Grottemeyer KH, Evers S, Fischer M, Husstedt IW. Piracetam versus acetylsalicylic acid in secondary stroke prophylaxis. A double-blind, randomized, parallel group, 2 year follow-up study. *J Neurol Sci.* 2000;181:65-72.
28. Li Y, Li D, Wang L. A prospective randomized controlled study on ticlopidine with aspirin for the prevention of ischemic cerebral stroke. *Journal of Clinical Neurology (Chinese).* 2000;13:146-148.
29. Mohr JP, Thompson JL, Lazar RM, Levin B, Sacco RL, Furie KL, Kistler JP, Albers GW, Pettigrew LC, Adams HP, Jr., Jackson CM, Pullicino P. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. *N Engl J Med.* 2001;345:1444-51.
30. Gorelick PB, Richardson D, Kelly M, Ruland S, Hung E, Harris Y, Kittner S, Leurgans S. Aspirin and ticlopidine for prevention of recurrent stroke in black patients: a randomized trial. *Jama.* 2003;289:2947-57.
31. Matias-Guiu J, Ferro JM, Alvarez-Sabin J, Torres F, Jimenez MD, Lago A, Melo T. Comparison of triflusal and aspirin for prevention of vascular events in patients after cerebral infarction: the TACIP Study: a randomized, double-blind, multicenter trial. *Stroke.* 2003;34:840-8.
32. Culebras A, Rotta-Escalante R, Vila J, Dominguez R, Abiusi G, Famulari A, Rey R, Bauso-Tosselli L, Gori H, Ferrari J, Reich E. Triflusal vs aspirin for prevention of cerebral infarction: a randomized stroke study. *Neurology.* 2004;62:1073-80.
33. Chairangsarit P, Sithinamsuwan P, Niyasom S, Udommongkol C, Nidhinandana S, Suwantamee J. Comparison between aspirin combined with dipyridamole versus aspirin alone within 48 hours after ischemic stroke event for prevention of recurrent stroke and improvement of neurological function: a preliminary study. *J Med Assoc Thai.* 2005;88 Suppl 3:S148-54.
34. Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. *Lancet.* 2006;367:1665-73.
35. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Flather MD, Haffner SM, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Brennan DM, Fabry-Ribaudo L, Booth J, Topol EJ. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. *N Engl J Med.* 2006;354:1706-17.
36. Bhatt DL, Flather MD, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Fabry-Ribaudo L, Hu T, Topol EJ, Fox KA. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. *J Am Coll Cardiol.* 2007;49:1982-8.
37. Shinohara Y, Nishimaru K, Sawada T, Terashi A, Handa S, Hirai S, Hayashi K, Tohgi H, Fukuuchi Y, Uchiyama S, Yamaguchi T, Kobayashi S, Kondo K, Otomo E, Gotoh F. Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS): A randomized, double-blind, aspirin-controlled trial. *Stroke.* 2008;39:1827-33.

Supplementary table 3. Baseline characteristics and design features of included trials

Trial name	Year of publication	Control group(s)	Dose, mg	Aspirin included in aspirin arm, n	Mean follow up duration, months	Annual event rate, %	Mean age, years	Male sex, %	TIA, %	AMI, %	DM, %	Current smoking, %	History of MI, %	PAOD, %	Time to inclusion, days	
AITIA ^{1,2}	1977	P	DB	1300	153	17	12.0	61	72	10	43	14	54	17	18	90
Reuther ³	1978	P	DB	1500	30	24	3.3	59	66	33	50	31	43	41	12	90
Canadian coop ⁴	1978	P,S,AS	DB	1300	144	26	10.6	††	68	98	-	-	-	-	-	90
Toulouse TIA ⁵	1982	P	OL	900	147	34	2.9	62.2	86	37	51	10	-	3	-	90
Italian TIA ⁶	1982	S	DB	1000	64	11	5.0	53.3	42	10	44	8	35	19	11	90
AICLA ⁷	1983	P	DB	990	198	36	5.2	63	66	16	65	22	62	7	5	365
Danish Coop ⁸	1983	P	DB	1000	101	33	8.3	59	76	71	28	-	75	11	18	30
Garde ⁹	1983	W	OL	1000	127	20	4.3	59.7	64	43	37	13	57	9	11	14
ACCSG ¹⁰	1985	AD	DB	1300	442	25	10.0	63.3	66	72	47	12		14	7	90

ESPS 2 ²²	1996	P, AD, D	D B	50	1649	24	9.5	66.8	58	24	60	15	24	14	22	90
CAPRIE ²³	1996	C	D B	325	3198	23	8.0	64.7	63	0	65	26	22	11	6	180
SPIRIT ²⁴	1997	W	O L	30	665	14	3.9	63.3	63	40	46	13	44	10	7	180
Lee ²⁵	1997	N	D B	100	222	20	5.8	62.8	61	0	59	27	43	7	-	42
Li ²⁶	1997	vario us	O L	50	301	30	4.9	68.1	69	18	38	-	28	12	-	90
Grotemeyer ²⁷	2000	Pi	D B	600	307	17	7.8	58	66	0	71	21	15	-	-	112
Li ²⁸	2000	T	O L	50	164	12	13.4	64	69	25	34	-	10	-	-	90
WARSS ²⁹	2001	W	D B	325	1103	24	8.9	62.6	59	6	68	31	31	23	-	30
AAASPS ³⁰	2003	T	D B	650	907	18	7.9	61.6	48	0	86	42	63	10	4	90
TACIP ³¹	2003	Tr	D B	325	1052	30	5.2	64.4	66	27	62	24	31	2	3	180
TAPIRSS ³²	2004	Tr	D B	325	216	19	7.2	65.2	68	19	70	18	28	6	4	180
Chairangarit ³³	2005	AD	O L	300	18	6	0.0	64.5	44	0	39	33	33	11	-	2

ESPRIT ³⁴	2006	AD	O L	75*	1376	42	4.0	63	65	33	59	18	37	7	4	180
CHARISMA § ³⁵	2006	CA	D B	75- 162+	2160	28	4.1	64	70	29	74	42	20	35	23	1825
CHARISMA stroke, MI, PAOD group ³⁶	2006	CA	D B	75- 162+	1611	28	3.8	64	73	0	70	31	22	47	-	1825
S-access ³⁷		Sa	D B	81	752	19	7.1	65	72	0	69	27	-	-	-	180

AD=aspirin and dipyridamole

AN=aspirin and nicardipine

AV=aspirin and vitamin E

AS=aspirin and sulfinpyrazone

C=clopidogrel

CA=clopidogrel and aspirin

D=dipyridamole

N=nicametate

P=placebo

Pi=piracetam

S=sulfinpyrazone

T=ticlopidin

Tr=triflusal

Sa=sarpogrelate

W=warfarin or oral anticoagulant

DB Double blind

OL Open label

* median dose

† a dose of 100 mg was used in all calculations

†† mean or median age not reported

§ baseline features from cerebrovascular (TIA and stroke) subgroup not reported separately

|| median

References

1. Fields WS, Lemak NA, Frankowski RF, Hardy RJ. Controlled trial of aspirin in cerebral ischemia. *Stroke*. 1977;8:301-14.
2. Fields WS, Lemak NA, Frankowski RF, Hardy RJ. Controlled trial of aspirin in cerebral ischemia. Part II: surgical group. *Stroke*. 1978;9:309-19.
3. Reuther R, Dorndorf W, Loew D. Behandlung transitorisch-ischämischer Attacken mit Azetylsalizylsäure Ergebnisse einer Doppelblindstudie. *MMW Munch Med Wochenschr*. 1980;122:795-8.
4. A randomized trial of aspirin and sulfinpyrazone in threatened stroke. The Canadian Cooperative Study Group. *N Engl J Med*. 1978;299:53-9.
5. Guiraud-Chaumeil B, Rascol A, David J, Boneu B, Clanet M, Bierme R. [Prevention of recurrences of cerebral ischemic vascular accidents by platelet antiaggregants. Results of a 3-year controlled therapeutic trial]. *Rev Neurol (Paris)*. 1982;138:367-85.
6. Candelise L, Landi G, Perrone P, Bracchi M, Brambilla G. A randomized trial of aspirin and sulfinpyrazone in patients with TIA. *Stroke*. 1982;13:175-9.
7. Bousser MG, Eschwege E, Haguenu M, Lefauconnier JM, Thibult N, Touboul D, Touboul PJ. "AICLA" controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia. *Stroke*. 1983;14:5-14.
8. Sorensen PS, Pedersen H, Marquardsen J, Petersson H, Heltberg A, Simonsen N, Munck O, Andersen LA. Acetylsalicylic acid in the prevention of stroke in patients with reversible cerebral ischemic attacks. A Danish cooperative study. *Stroke*. 1983;14:15-22.

9. Garde A, Samuelsson K, Fahlgren H, Hedberg E, Hjerne LG, Ostman J. Treatment after transient ischemic attacks: a comparison between anticoagulant drug and inhibition of platelet aggregation. *Stroke*. 1983;14:677-81.
10. Persantine Aspirin Trial in cerebral ischemia. Part II: Endpoint results. The American-Canadian Co-Operative Study group. *Stroke*. 1985;16:406-15.
11. High-dose acetylsalicylic acid after cerebral infarction. A Swedish Cooperative Study. *Stroke*. 1987;18:325-34.
12. Tohgi H, Murakami M. [Pathophysiology and treatment of thrombosis. (2) The effect of ticlopidine on TIA compared with aspirin. A double-blind, 12-month and open 24-month follow-up study]. *Nippon Naika Gakkai Zasshi*. 1987;76:49-52.
13. Boysen G, Sorensen PS, Juhler M, Andersen AR, Boas J, Olsen JS, Joensen P. Danish very-low-dose aspirin after carotid endarterectomy trial. *Stroke*. 1988;19:1211-5.
14. Marti Masso JF, Lozano R. Nifedipine in the prevention of cerebral infarction. *Clin Ther*. 1990;12:344-51.
15. United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: interim results. UK-TIA Study Group. *Br Med J (Clin Res Ed)*. 1988;296:316-20.
16. Farrell B, Godwin J, Richards S, Warlow C. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. *J Neurol Neurosurg Psychiatry*. 1991;54:1044-54.
17. Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. The SALT Collaborative Group. *Lancet*. 1991;338:1345-9.
18. Hass WK, Easton JD, Adams HP, Jr., Pryse-Phillips W, Molony BA, Anderson S, Kamm B. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. *N Engl J Med*. 1989;321:501-7.
19. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. The Dutch TIA Trial Study Group. *N Engl J Med*. 1991;325:1261-6.
20. Smirne S. Triflusal in the prevention of cerebrovascular attacks. *Giornale di Gerontologia*. 1995;43:563-569.
21. Steiner M, Glantz M, Lekos A. Vitamin E plus aspirin compared with aspirin alone in patients with transient ischemic attacks. *Am J Clin Nutr*. 1995;62:1381S-1384S.
22. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. *J Neurol Sci*. 1996;143:1-13.
23. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. *Lancet*. 1996;348:1329-39.
24. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group. *Ann Neurol*. 1997;42:857-65.
25. Lee TK, Chan KW, Huang ZS, Ng SK, Lin RT, Po HL, Yuan RY, Lai ML, Chang TW, Yan SH, Deng JC, Liu LH, Lee KY, Lie SK, Sung SM, Hu HH. Effectiveness of low-dose ASA in prevention of secondary ischemic stroke, the ASA Study Group in Taiwan. *Thromb Res*. 1997;87:215-24.
26. Li YZ, Li DN, Hu ZQ, Fan RY, Liu BM, Zhu SW, Cheng GZ, Wang SJ, Li CG, Zheng JL, Zhang SG, Ma RZ, Hu ZK, Cui BW, Chi HW. Multicenter controlled trial of aspirin in secondary prevention of ischemia cerebrovascular disease in aged. *Chinese Journal of Prevention and Control of Chronic Non-Communicable Disease*. 1997;5:221-224.

27. Grottemeyer KH, Evers S, Fischer M, Husstedt IW. Piracetam versus acetylsalicylic acid in secondary stroke prophylaxis. A double-blind, randomized, parallel group, 2 year follow-up study. *J Neurol Sci.* 2000;181:65-72.
28. Li Y, Li D, Wang L. A prospective randomized controlled study on ticlopidine with aspirin for the prevention of ischemic cerebral stroke. *Journal of Clinical Neurology (Chinese).* 2000;13:146-148.
29. Mohr JP, Thompson JL, Lazar RM, Levin B, Sacco RL, Furie KL, Kistler JP, Albers GW, Pettigrew LC, Adams HP, Jr., Jackson CM, Pullicino P. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. *N Engl J Med.* 2001;345:1444-51.
30. Gorelick PB, Richardson D, Kelly M, Ruland S, Hung E, Harris Y, Kittner S, Leurgans S. Aspirin and ticlopidine for prevention of recurrent stroke in black patients: a randomized trial. *Jama.* 2003;289:2947-57.
31. Matias-Guiu J, Ferro JM, Alvarez-Sabin J, Torres F, Jimenez MD, Lago A, Melo T. Comparison of triflusal and aspirin for prevention of vascular events in patients after cerebral infarction: the TACIP Study: a randomized, double-blind, multicenter trial. *Stroke.* 2003;34:840-8.
32. Culebras A, Rotta-Escalante R, Vila J, Dominguez R, Abiusi G, Famulari A, Rey R, Bauso-Tosselli L, Gori H, Ferrari J, Reich E. Triflusal vs aspirin for prevention of cerebral infarction: a randomized stroke study. *Neurology.* 2004;62:1073-80.
33. Chairangsarit P, Sithinamsuwan P, Niyasom S, Udommongkol C, Nidhinandana S, Suwantamee J. Comparison between aspirin combined with dipyridamole versus aspirin alone within 48 hours after ischemic stroke event for prevention of recurrent stroke and improvement of neurological function: a preliminary study. *J Med Assoc Thai.* 2005;88 Suppl 3:S148-54.
34. Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. *Lancet.* 2006;367:1665-73.
35. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Flather MD, Haffner SM, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Brennan DM, Fabry-Ribaudo L, Booth J, Topol EJ. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. *N Engl J Med.* 2006;354:1706-17.
36. Bhatt DL, Flather MD, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Fabry-Ribaudo L, Hu T, Topol EJ, Fox KA. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. *J Am Coll Cardiol.* 2007;49:1982-8.
37. Shinohara Y, Nishimaru K, Sawada T, Terashi A, Handa S, Hirai S, Hayashi K, Tohgi H, Fukuuchi Y, Uchiyama S, Yamaguchi T, Kobayashi S, Kondo K, Otomo E, Gotoh F. Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS): A randomized, double-blind, aspirin-controlled trial. *Stroke.* 2008;39:1827-33.

Supplementary Table 4 Summarized characteristics of included studies

<i>Feature</i>	<i>Number of aspirin arms of RCT reporting feature, n</i>	<i>Mean (SD)</i>	<i>Minimum and maximum</i>
Age, years	34	63 (4)	53-71
Male sex,%	36	64 (9)	42-86
TIA,%	35	38 (32)	0-100
Hypertension,%	35	51 (14)	28-86
Diabetes mellitus,%	32	18 (10)	4-41
Current smoking,%	29	41 (16)	15-75
Peripheral artery occlusive disease,%	25	9 (6)	3-25
History of myocardial infarction, %	29	12(8)	0-41
Aspirin dose, mg	34	606 (522)	30-1500
Maximum allowed delay between last symptom (TIA or stroke) and randomization, days	36	157 (297)	2-1825